← Leaderboards
Malgorzata Simm
St. Luke'S-Roosevelt Inst For Hlth Scis
$4,894,739
Attributed
$4,894,739
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $702.9K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,894,739 · 5
By mechanism
R01$2,821,828 · 2
U01$1,241,014 · 1
R15$428,397 · 1
R21$403,500 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cytokine”
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$83,965,880
- David Heimbrook · Leidos Biomedical Research, Inc.$56,453,265
- Fulton T Crews · University Of North Carolina Chapel Hill$36,249,590
- Marianne Ward · Duke University$34,872,957
- Joren C Madsen · Massachusetts General Hospital$33,058,731
- Barton F Haynes · Duke University$29,068,807
Research focus
CytokineCellsCell LineBinding (Molecular Function)Tnfrsf5 GeneMutantVirusInfectionNuclearOligonucleotidesProteinsComplexRecombinantsResponseBaseDoseMediatingLengthR FactorsRecombinant ProteinsOrganKineticsMacrophagePhenotype
Grant awards (15)
The anatomical and functional study of the thymus - defining the milestones of the thymic aging in the elderly human population$428,397
R15 · FY2024 · AG · contact PI
CTCF peptides - a new therapeutic alternative to target HIV in the brain.$398,370
R01 · FY2012 · NS · contact PI
CTCF peptides - a new therapeutic alternative to target HIV in the brain.$398,370
R01 · FY2011 · NS · contact PI
CTCF peptides - a new therapeutic alternative to target HIV in the brain.$402,435
R01 · FY2010 · NS · contact PI
CTCF peptides - a new therapeutic alternative to target HIV in the brain.$406,500
R01 · FY2009 · NS · contact PI
CTCF peptides - a new therapeutic alternative to target HIV in the brain.$406,500
R01 · FY2008 · NS · contact PI
HRF, an NFkB antagonist targeting multiple pathogenes$296,367
U01 · FY2008 · AI · contact PI
HRF, an NFkB antagonist targeting multiple pathogenes$306,858
U01 · FY2007 · AI · contact PI
HRF, an NFkB antagonist targeting multiple pathogenes$310,024
U01 · FY2006 · AI · contact PI
HRF, an NFkB antagonist targeting multiple pathogenes$327,765
U01 · FY2005 · AI
Macrophage-mediated delivery of HIV-1 Vaccine$201,750
R21 · FY2005 · MH
Macrophage-mediated delivery of HIV-1 Vaccine$201,750
R21 · FY2004 · MH
Inducible Cellular Resistance to HIV-1 infection.$271,250
R01 · FY2003 · AI
Inducible Cellular Resistance to HIV-1 infection.$271,250
R01 · FY2002 · AI
Inducible Cellular Resistance to HIV-1 infection.$267,153
R01 · FY2001 · AI